Lanvexin

Venlafaxine, the active ingredient in Lanvexin, is a Serotonin‑Norepinephrine Reuptake Inhibitor (SNRI) presented as an oral dosage form for oral use. It is prescribed for the treatment of major depressive disorder and several anxiety‑related conditions in adult patients. The medication works by modulating neurotransmitter levels to improve mood and anxiety symptoms.

GNH USA supplies Lanvexin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured products for diverse healthcare markets.

Lanvexin (venlafaxine) is used to treat disorders within the mood and anxiety disease families. - Major depressive disorder: reduces depressive symptoms and improves overall mood in adults. - Generalized anxiety disorder: lessens excessive worry and associated physical symptoms. - Panic disorder: decreases frequency and severity of panic attacks. - Social anxiety disorder: helps reduce fear of social situations and improves functioning. - Obsessive‑compulsive disorder (off‑label): may lessen obsessive thoughts and compulsive behaviors.

Venlafaxine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset, often transient. - Headache: dull or throbbing pain, usually resolves with continued therapy. - Dry mouth: reduced salivation causing discomfort. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Serotonin syndrome: agitation, hyperthermia, muscle rigidity when combined with other serotonergic agents. - Increased blood pressure: may require regular monitoring. - Suicidal thoughts: emergence of new or worsening ideation, especially early in treatment.

Before initiating therapy, clinicians should consider several safety measures. - Cardiovascular monitoring: check blood pressure and heart rate regularly, especially during dose escalation. - Suicidality risk: monitor for emerging suicidal thoughts, particularly in early treatment or dose changes. - Serotonin syndrome: be vigilant for signs such as agitation, hyperthermia, and muscle rigidity when combined with serotonergic agents. - Discontinuation syndrome: taper gradually under medical supervision to avoid withdrawal symptoms. - Pregnancy and lactation: evaluate risk‑benefit ratio before prescribing to pregnant or nursing women. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Venlafaxine can interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertensive crisis and serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, triptans): may precipitate serotonin syndrome. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase venlafaxine plasma levels.

Moderate Interactions (Monitor Closely): - NSAIDs or anticoagulants: heightened risk of bleeding. - Antihypertensive agents: possible additive blood‑pressure‑lowering effect.